240 related articles for article (PubMed ID: 27776453)
1. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
Hanefeld M; Raccah D; Monnier L
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
[TBL] [Abstract][Full Text] [Related]
2. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
3. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
Forst T
Expert Opin Pharmacother; 2016 Aug; 17(12):1703-8. PubMed ID: 27341040
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
Porcellati F; Lucidi P; Bolli GB; Fanelli CG
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
Forst T; Pfützner A
Expert Opin Pharmacother; 2013 Nov; 14(16):2281-96. PubMed ID: 24087882
[TBL] [Abstract][Full Text] [Related]
7. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.
Horowitz M; Rayner CK; Jones KL
Adv Ther; 2013 Feb; 30(2):81-101. PubMed ID: 23423907
[TBL] [Abstract][Full Text] [Related]
9. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
Bolli GB; Owens DR
Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
[TBL] [Abstract][Full Text] [Related]
10. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
11. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
Trujillo JM; Goldman J
Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
[TBL] [Abstract][Full Text] [Related]
12. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
Werner U
J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
[TBL] [Abstract][Full Text] [Related]
13. Lixisenatide for type 2 diabetes mellitus.
Christensen M; Knop FK; Vilsbøll T; Holst JJ
Expert Opin Investig Drugs; 2011 Apr; 20(4):549-57. PubMed ID: 21391833
[TBL] [Abstract][Full Text] [Related]
14. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
Aronson R
Expert Rev Clin Pharmacol; 2013 Nov; 6(6):603-12. PubMed ID: 24147558
[TBL] [Abstract][Full Text] [Related]
15. Lixisenatide for the treatment of type 2 diabetes.
Petersen AB; Knop FK; Christensen M
Drugs Today (Barc); 2013 Sep; 49(9):537-53. PubMed ID: 24086950
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
17. Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.
Charpentier J; Waget A; Klopp P; Magnan C; Cruciani-Guglielmacci C; Lee SJ; Burcelin R; Grasset E
Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G671-G684. PubMed ID: 30070580
[TBL] [Abstract][Full Text] [Related]
18. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
Quast DR; Schenker N; Menge BA; Nauck MA; Kapitza C; Meier JJ
Diabetes Care; 2020 Sep; 43(9):2137-2145. PubMed ID: 32647054
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.
Davidson JA
Postgrad Med; 2015; 127(8):827-41. PubMed ID: 26428031
[TBL] [Abstract][Full Text] [Related]
20. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
McCarty D; Coleman M; Boland CL
Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
